InvestmentMay 19, 2026, 06:08 AM
InMed Pharmaceuticals Amends Armistice Option Exercise Price to $0.80
AI Summary
InMed Pharmaceuticals Inc. has amended its preferred investment option agreement with Armistice Capital Master Fund Ltd., drastically reducing the exercise price for up to 278,761 common shares. The exercise price was changed from $16.60 to $0.80 per share. These options were originally issued in October 2023 and were subject to adjustment following a 1-for-20 share consolidation, which had previously set the price at $16.60.
Key Highlights
- InMed Pharmaceuticals amended preferred investment options with Armistice Capital.
- Exercise price reduced from $16.60 to $0.80 per common share.
- Options cover up to 278,761 common shares.
- Original options dated October 26, 2023, at $0.83 per share (pre-split).
- Price reflects adjustment from a prior 1-for-20 share consolidation.
Price Impact
More from INM